Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SOLO-1: practice changing results for advanced ovarian cancer

Susana Banerjee • 21 Oct 2018
ESMO 2018
Gynecological Cancer Ovarian Cancer Olaparib
SOLO-1

SOLO-1 (NCT01844986) is the first Phase III study of a maintenance PARP inhibitor in the frontline setting in advanced ovarian cancer. Susana Banerjee, MBBS, PhD, FRCP, from the Royal Marsden NHS Foundation Trust, London, UK, describes the practice changing results from this study, presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Patients with BRCA mutated ovarian cancer who had previously received first-line platinum-based chemotherapy were given olaparib as a monotherapy. These women had a clinically significant benefit with regards to overall survival.

More from Susana Banerjee

Women for Oncology: initiatives at ESMO 2018
2:06
Women for Oncology: initiatives at ESMO 2018
Susana Banerjee • 21 Oct 2018
Standard of care and progress with PARP inhibitors for ovarian cancer
6:14
Standard of care and progress with PARP inhibitors for ovarian cancer
Susana Banerjee • 21 Oct 2018

Related Videos

The future of antibody-drug conjugates in endometrial cancer
1:10
The future of antibody-drug conjugates in endometrial cancer
Linda Mileshkin • 30 May 2026
B7-H4-directed ADC in endometrial versus ovarian cancer
0:43
B7-H4-directed ADC in endometrial versus ovarian cancer
Linda Mileshkin • 30 May 2026
Barriers to cervical cancer screening among rural women in India
0:54
Barriers to cervical cancer screening among rural women in India
Shailendra Dandge • 31 May 2026
A community-based model for cervical cancer screening uptake in rural India
8:39
A community-based model for cervical cancer screening uptake in rural India
Shailendra Dandge • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals